Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

GSK

8 abstracts

9 posters

Poster
CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting β2-agonists (ICS/LABA)
Poster
Mepolizumab Therapy Improves Most Bothersome Symptoms in Patients With Hypereosinophilic Syndrome (HES)
Poster
Mepolizumab Improves Health-Related Quality of Life for Patients With Chronic Rhinosinusitis With Nasal Polyps: Data From the SYNAPSE Study
Poster
Mepolizumab Reduces Disease Symptoms for Patients With Chronic Rhinosinusitis With Nasal Polyps: Data From the SYNAPSE Study
Poster
Impact of Baseline Clinical Asthma Characteristics on the Response to Mepolizumab: A Post Hoc Meta-analysis of Two Phase III Trials
Poster
Impact of Baseline Clinical Asthma Characteristics on the Response to Mepolizumab: A Post Hoc Meta-analysis of Two Phase III Trials
Poster
CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting β2-agonists (ICS/LABA)
Poster
Impact of Baseline Clinical Asthma Characteristics on the Response to Mepolizumab: A Post Hoc Meta-analysis of Two Phase III Trials
Poster
Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 DREAMM-5 platform sub-study 3
Abstract
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Org: GSK, Flatiron Health, San Francisco, CA,
Abstract
Patient (pt) interview–based content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0).
Org: GSK plc, GSK, Evidera, Inc,
Abstract
Real-world treatment patterns and outcomes in US patients (pts) with advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy (PBC) and anti–PD-(L)1 treatment.
Org: NYU Perlmutter Cancer Center, GSK plc, GSK,
Abstract
Patient (pt) experience with and perceptions of transfusion-dependent (TD) and transfusion-independent (TI) myelofibrosis (MF): A qualitative interview study.
Org: GSK plc, Evidera, Inc, GSK,